ClinConnect ClinConnect Logo
Search / Trial NCT00232791

The Study to Compare Cypher Versus Cypher Select in Treating Cornary Artery Lesions.

Launched by CORDIS CORPORATION · Oct 4, 2005

Trial Information

Current as of June 17, 2025

Completed

Keywords

ClinConnect Summary

This is a multicenter (up to 10 sites), open, prospective, 2-arm, unbalanced, randomized study designed to assess the safety and effectiveness of the CYPHER SELECT™ Sirolimus-eluting Coronary Stent as compared to the CYPHER™ Sirolimus-eluting Coronary Stent. A total of 100 patients will be entered in the study and will be randomized on a 2:1 basis to the CYPHER SELECT™ stent or the CYPHER™ stent. 100 patients with de novo native coronary artery lesions \<23 mm in length and more than 2.5 to less than 3.5 mm in diameter by visual estimate who meet all eligibility criteria will be either rand...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B\&C, I-II-III) OR patients with documented silent ischemia;
  • 2. Single treatment of de novo lesion in a coronary artery which can be appropriately covered by a study stent up to 23mm in length in patients with single or multivessel disease; patients with multiple lesions can be included only if the other lesions are successfully treated before the target lesion;
  • 3. Target lesion is more than 2.5 and less than 3.5mm in diameter (visual estimate);
  • 4. Target lesion is located in a native coronary artery with a maximum lesion length that can be adequately covered by a single 23 mm stent;
  • 5. Target lesion stenosis is \> 50% and \< 100% (visual estimate).
  • Exclusion Criteria:
  • 1. A Q-wave or non-Q-wave myocardial infarction within the preceding 72 hours unless the CK and CK-MB enzymes are back to normal;
  • 2. Unprotected left main coronary disease with more than 50% stenosis;
  • 3. Significant (\>50%) stenoses proximal or distal to the target lesion that might require revascularization or impede runoff;
  • 4. Have an ostial target lesion;
  • 5. Angiographic evidence of thrombus within target lesion;
  • 6. Calcified lesions which cannot be successfully predilated;
  • 7. Ejection fraction less than 30%;
  • 8. Totally occluded vessel (TIMI 0 level);
  • 9. Direct Stenting;

About Cordis Corporation

Cordis Corporation is a leading global provider of innovative cardiovascular and endovascular solutions, dedicated to advancing the treatment of vascular diseases. With a strong emphasis on research and development, Cordis focuses on delivering high-quality medical devices that enhance patient outcomes and improve procedural efficiency. The company is committed to clinical excellence and rigorous regulatory compliance, actively engaging in clinical trials to support the safety and efficacy of its products. Through collaboration with healthcare professionals and continuous innovation, Cordis aims to address unmet medical needs and foster advancements in the field of interventional medicine.

Locations

Liverpool, , United Kingdom

Patients applied

0 patients applied

Trial Officials

R. H. Stables, MD

Principal Investigator

Cardiothoracic Centre Liverpool

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials